Phase Ib Study of FURMONERTINIB in Patients with NSCLC Having Exon 20 Insertion Mutation
Clinical trial NCT04958967 · WITHDRAWN
Trial details
- NCT number
- NCT04958967
- Sponsor
- Allist Pharmaceuticals, Inc.
- Status
- WITHDRAWN
- Phase
- Phase 1
- Study type
- INTERVENTIONAL
- Start date
- 2021-10-01
- Primary completion
- 2022-05-01
- Enrollment
- 0
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.